Biologic Therapy for IBD Not Tied to Higher Risk of Major Heart Events
(MedPage Today) -- In contrast to recent data on tofacitinib (Xeljanz) in rheumatoid arthritis, patients with inflammatory bowel disease (IBD) who received biologic therapies appeared to have a lower risk for a major adverse cardiovascular event...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Arthritis | Cardiology | Cardiovascular | Gastroenterology | Heart | Inflammatory Bowel Disease | Rheumatoid Arthritis | Rheumatology